Literature DB >> 24387205

CD26: a key molecule in immune regulation and autoimmune diseases.

Osamu Hosono1, Kei Ohnuma, Nam H Dang, Chikao Morimoto.   

Abstract

Abstract In this review, we focus on major aspects of the biology of CD26, a dipeptidyl peptidase IV (DPPIV)-containing surface glycoprotein with multiple functions. In particular, we discuss findings demonstrating that CD26/DPPIV has an essential role in immune regulation as a T cell activation molecule and a regulator of chemokine function. We also review recent studies that identify key cellular molecules that physically associate with CD26 and the potential consequences of their interaction, including those with clinically related implications. Furthermore, we present work suggesting a role for CD26 in the pathophysiology of immune-mediated disorders as well as autoimmune diseases. We present recent studies that investigate the potential role of CD26 as a molecular target for novel treatment modalities for immune-mediated diseases, with work involving the use of anti-CD26 monoclonal antibody, DPPIV inhibitors, and soluble CD26 molecules.

Entities:  

Year:  2003        PMID: 24387205     DOI: 10.3109/s10165-003-0224-y

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  2 in total

Review 1.  Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Authors:  Emile Verhulst; Delphine Garnier; Ingrid De Meester; Brigitte Bauvois
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

2.  Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.

Authors:  Ivana Z Matić; Marija Ðorđić; Nađa Grozdanić; Ana Damjanović; Branka Kolundžija; Aleksandra Erić-Nikolić; Radan Džodić; Miomir Šašić; Srđan Nikolić; Danijela Dobrosavljević; Sanvila Rašković; Slađana Andrejević; Dušica Gavrilović; Oscar J Cordero; Zorica D Juranić
Journal:  BMC Immunol       Date:  2012-08-21       Impact factor: 3.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.